Netrin-1 as a novel therapeutic target of medulloblastoma
| Project/Area Number |
18K08984
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56010:Neurosurgery-related
|
|---|
| Research Institution | Hiroshima International University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 軸索誘導因子 / 血管新生 / 転移 / 上皮間葉転換 / netrin-1 / 癌幹細胞 / 髄芽腫 / ネトリン |
|---|
| Outline of Final Research Achievements |
Netrin-1, a chemoattractant factor in the neuronal system, promotes tumor progression by enhancing angiogenesis and metastasis. Our recent studies demonstrate that netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis in vitro and in vivo. Here, we analyze biological mechanism of netrin-1 in medulloblastoma using mouse model. In a xenograft model, tumor growth was increased when medulloblastoma cells overexpressing netrin-1 were implanted vs. parental cells. Furthermore, immunohistochemical analysis of CD31-expressing endothelial cell demonstrated numerous blood vessels in netrin-1-medulloblastoma. As a molecular mechanism, we find that epithelial mesenchymal transition (EMT)-related molecules are upregulated in netrin-1-medulloblasoma.
|
| Academic Significance and Societal Importance of the Research Achievements |
軸索誘導因子（リガンド）およびそのレセプターは、神経軸索伸長の制御因子として同定、解析されてきた。その後の解析によって、軸索誘導因子およびそのレセプターが腫瘍や血管新生にも影響をもたらすことが理解され、腫瘍の治療標的として研究が進んでいる。よって、本研究で明らかになった髄芽腫におけるnetrin-1の分子機序をさらに解析することによって腫瘍・血管新生に対する阻害剤開発に貢献するだけではなく、その他の分野（特に神経変性疾患、炎症関連疾患）への応用も可能であり創薬分野に大きく貢献できるものと考える。
|
Report
(5 results)
Research Products
(14 results)
-
-
[Journal Article] Functionally confirmed compound heterozygous ADAM17 missense loss-of-function variants cause neonatal inflammatory skin and bowel disease 12021
Author(s)
Imoto I, Saito M, Suga K, Kohmoto T, Otsu M, Horiuchi K, Nakayama H, Higashiyama S, Sugimoto M, Sasaki A, Homma Y, Shono M, Nakagawa R, Hayabuchi Y, Tange S, Kagami S, Masuda K
-
Journal Title
Scientific reports
Volume: 11
Issue: 1
Pages: 9552-9552
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
